BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND KDM6A, O15550, UTX, 7403, ENSG00000147050, DKFZp686A03225, RP13-886N14_3, MGC141941, bA386N14_2 AND Treatment
30846 results:

  • 1. Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.
    Rosar F; Burgard C; David S; Marlowe RJ; Bartholomä M; Maus S; Petto S; Khreish F; Schaefer-Schuler A; Ezziddin S
    Sci Rep; 2024 May; 14(1):11271. PubMed ID: 38760451
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Incretin-based drugs decrease the incidence of prostate cancer in type 2 diabetics: A pooling-up analysis.
    Lin Y; Xu G; Li L; Xiang J; Zhai L
    Medicine (Baltimore); 2024 May; 103(20):e38018. PubMed ID: 38758855
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Development and Validation of a Multimodality Model Based on Whole-Slide Imaging and Biparametric MRI for Predicting Postoperative Biochemical Recurrence in prostate cancer.
    Hu C; Qiao X; Huang R; Hu C; Bao J; Wang X
    Radiol Imaging Cancer; 2024 May; 6(3):e230143. PubMed ID: 38758079
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. prostate intra-fraction motion recorded by transperineal ultrasound.
    Ballhausen H; Belka C; Li M
    Sci Data; 2024 May; 11(1):504. PubMed ID: 38755158
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed prostate cancer.
    Tward JD; Lenz L; Gutin A; Clegg W; Kasten CR; Finch R; Cohen T; Michalski J; Kishan AU
    JCO Precis Oncol; 2024 May; 8():e2300722. PubMed ID: 38748970
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. First in vitro measurement of VHEE relative biological effectiveness (RBE) in lung and prostate cancer cells using the ARES linac at DESY.
    Wanstall HC; Burkart F; Dinter H; Kellermeier M; Kuropka W; Mayet F; Vinatier T; Santina E; Chadwick AL; Merchant MJ; Henthorn NT; Köpke M; Stacey B; Jaster-Merz S; Jones RM
    Sci Rep; 2024 May; 14(1):10957. PubMed ID: 38740830
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Projected estimates of cancer in Canada in 2024.
    Brenner DR; Gillis J; Demers AA; Ellison LF; Billette JM; Zhang SX; Liu JL; Woods RR; Finley C; Fitzgerald N; Saint-Jacques N; Shack L; Turner D;
    CMAJ; 2024 May; 196(18):E615-E623. PubMed ID: 38740416
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Anorectal function and symptoms 6 months after robot-assisted laparoscopic radical prostatectomy: a single-center study.
    Psarias T; Walter S; Holmbom M; Khayoun Issa I; Abdul-Sattar Aljabery F; Hallböök O
    Scand J Urol; 2024 May; 59():104-108. PubMed ID: 38738961
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Inhibition of prostate cancer Cell Survival and Proliferation by Carnosic Acid Is Associated with Inhibition of Akt and Activation of AMPK Signaling.
    Nadile M; Sze NSK; Fajardo VA; Tsiani E
    Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732504
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Chronic radiation proctitis refractory to steroid enema was successfully treated by metformin and sodium butyrate: a case report.
    Chi MS; Hsieh PH; Huang SH; Hsu HC; Chi KH
    J Med Case Rep; 2024 May; 18(1):239. PubMed ID: 38725071
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Increasing the radiation-induced cytotoxicity by silver nanoparticles and docetaxel in prostate cancer cells.
    Hatami Zharabad S; Mohammadian M; Zohdi Aghdam R; Hassanzadeh Dizaj M; Behrouzkia Z
    Mol Biol Rep; 2024 May; 51(1):633. PubMed ID: 38724835
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds.
    Kadry MO; Abdel-Megeed RM
    PLoS One; 2024; 19(5):e0302264. PubMed ID: 38723038
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Novel role of LLGL2 silencing in autophagy: reversing epithelial-mesenchymal transition in prostate cancer.
    Hong GL; Kim KH; Kim YJ; Lee HJ; Cho SP; Han SY; Yang SW; Lee JS; Kang SK; Lim JS; Jung JY
    Biol Res; 2024 May; 57(1):25. PubMed ID: 38720397
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. treatment Related Acute Toxicities Between treatment with 3D-CRT and IMRT in Localised prostate cancer.
    Hanif S; Osmani AH; Mallick J
    J Coll Physicians Surg Pak; 2024 May; 34(5):573-577. PubMed ID: 38720219
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Active surveillance of low-grade prostate cancer using the SurACaP Criteria: A multi-institutional series with a median follow-up of 10years.
    Leclercq L; Bastide C; Lechevallier E; Walz J; Charvet AL; Gondran-Tellier B; Campagna J; Savoie PH; Long-Depaquit T; Daniel L; Rossi D; Pignot G; Baboudjian M
    Fr J Urol; 2024 Mar; 34(2):102571. PubMed ID: 38717459
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Identifying risk factors for hypoxemia during emergence from anesthesia in patients undergoing robot-assisted laparoscopic radical prostatectomy.
    Zhang Q; Zhu L; Yuan S; Lu S; Zhang X
    J Robot Surg; 2024 May; 18(1):200. PubMed ID: 38713381
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Impact of COVID-19 on the time to counseling and treatment of prostate cancer.
    Filipas DK; Pose RM; Marks P; Tennstedt P; Beyer B; Tilki D; Isbarn H; Maurer T; Ludwig TA; Heinzer H; Steuber T
    Aging Male; 2024 Dec; 27(1):2347465. PubMed ID: 38712892
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Deep learning-based whole-body PSMA PET/CT attenuation correction utilizing Pix-2-Pix GAN.
    Ma KC; Mena E; Lindenberg L; Lay NS; Eclarinal P; Citrin DE; Pinto PA; Wood BJ; Dahut WL; Gulley JL; Madan RA; Choyke PL; Turkbey IB; Harmon SA
    Oncotarget; 2024 May; 15():288-300. PubMed ID: 38712741
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Irradiated microparticles suppress prostate cancer by tumor microenvironment reprogramming and ferroptosis.
    Deng Z; Li B; Yang M; Lu L; Shi X; Lovell JF; Zeng X; Hu W; Jin H
    J Nanobiotechnology; 2024 May; 22(1):225. PubMed ID: 38705987
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. A mitochondrion-targeted cyanine agent for NIR-II fluorescence-guided surgery combined with intraoperative photothermal therapy to reduce prostate cancer recurrence.
    Liu C; Chang Z; Chen K; Xue Q; Shu B; Wei Z; Zhou X; Guo L; Zhang Y; Pan Y; Cao Q; Liang H; Sun Q; Zhang X
    J Nanobiotechnology; 2024 May; 22(1):224. PubMed ID: 38702709
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 1543.